HKSTP Leads Hong Kong Innovators to Global Stage via VivaTech Paris and BIO San Diego

Hong Kong Science and Technology Parks Corporation (HKSTP) will be leading two major overseas delegations in June—VivaTech 2026 in Paris, Europe’s leading startup showcase, and BIO International Convention (BIO) 2026 in San Diego, the world’s largest life and health technology event. The twin missions put Hong Kong innovation on a global stage at an unprecedented scale to open new paths for collaboration, investment and two-way market access for tech ventures from Hong Kong, as well as for European and US innovators seeking opportunities in Hong Kong, the Greater Bay Area (GBA) and across Asia.

HKSTP will be leading 2 major delegations to VivaTech in Paris and the BIO International Convention 2026 in San Diego within June, bringing Hong Kong innovation to the global stage and unlocking unprecedented growth opportunities.

“June marks a landmark moment in HKSTP’s mission to rally a global tech community to reinforce Hong Kong’s position as a launchpad to success, also to promote the vibrancy and sustainability of our innovation and technology (I&T) ecosystem,” said Terry Wong, CEO, HKSTP. “Our priorities lie with AI and biotech, both fields speak unmeasurable value and impact that would set us apart in this digital age, and of course, are core to connecting innovation ecosystems of the US, Europe and the Chinese Mainland as an international I&T hub.”

Terry Wong, CEO of HKSTP, said: “June marks a landmark moment in HKSTP’s mission to rally a global tech community to reinforce Hong Kong’s position as a launchpad to success, also to promote the vibrancy and sustainability of our innovation and technology (I&T) ecosystem.”

VivaTech 2026: A Decade of Innovation
As VivaTech celebrates its 10th year serving as a beacon to startups looking to enter Europe, HKSTP returns as a premier I&T ecosystem orchestrator, from 17 to 20 June, supporting the Hong Kong Trade Development Council (HKTDC) in organising the Hong Kong Tech Pavilion showcases innovative solutions of 24 Hong Kong tech ventures, among which 16 are incubated by HKSTP, spans AI, green- and health tech, to connect with the local I&T community, the European market, and global innovators through matching sessions, mixers, and more. Notable tech ventures include:

Antonio Ng, CEO of Formwork IO, made Top 30 of the Tech For Change Awards by VivaTech, introduced the latest ‘Matcha Tile,’ making its debut with a bio-pigment palette derived from actual matcha waste, reflecting a rapid growing market demand for the ingredient.

Formwork IO — A ClimateTech materials company that transforms upcycled industrial by-products and wellness-focused bio-pigments, into building materials that actively sequester atmospheric CO2, uniting carbon leadership, circularity, and human wellness in a single material innovation, has made Top 30 of the Tech For Change Awards by VivaTech.

Herman Chan, Managing Director of LeafIoT (2nd from left) shared the concept behind its green asset management solution, was to absorb the best of both traditional Eastern diagnostics and modern AI, and analyse health risks of trees in a compact urban- or vast rural settings.

LeafIoT — A pioneer in green asset management introducing a groundbreaking East-meets-West smart tree management system, translating the traditional Eastern diagnostics into modern AI technology to significantly extend the lifespan of trees and restore natural ecological balance in an urban setting, empowering governments and enterprises to achieve green and low-carbon goals securely.

Ivan Lau, CEO of Pantheon Lab shared real-life applications and impact of its digital human interface solution, offering corporation and organisations an alternative in directing their resources more efficiently.

Dr Cynthia Shum, Business Development Manager of GenEditBio, will join HKSTP's delegation to US BIO and showcase their vivo genome editing therapies (also known as "DNA surgery").

Pantheon Lab — A leading GenAI company providing advanced Agentic AI and digital human interface solutions span banking, public services, government agencies, and large enterprises.

BIO 2026: The largest-ever Hong Kong Biotech Debut
Showcasing growing global biotech momentum, HKSTP will organize the largest-ever Hong Kong Pavilion at BIO 2026 from 22 – 25 June, featuring double the number of participating organizations and exhibition area size compared to last year. Joining forces with InvestHK as the co-organiser, HKTDC as the supporting organisation, and five renowned local universities - The University of Hong Kong, The Chinese University of Hong Kong, The Hong Kong University of Science and Technology, City University of Hong Kong, and The Hong Kong Polytechnic University - the record-breaking delegation will showcase life and health innovation from 41 tech firms, institutes, and university spin-offs from Hong Kong. The innovation spans AI-enabled biotech, therapeutics, diagnostics, and pharma innovation, with potential outstanding "First-in-Class" and "Best-in-Class" assets.

Beyond the BIO 2026 Hong Kong Pavilion, HKSTP CEO Mr Terry Wong will attend the "Translating Innovation Across Borders: Creating Global Gateways for Biotech Startups" panel sharing session. This panel session will explore how structured programmes can create intentional pathways for international startups to integrate into leading biotech ecosystems. Mr. Wong will share his insights on cutting-edge biotech trends, Hong Kong’s strengths on life and health tech development, and HKSTP’s orchestrating role of building global bridge for nurturing global startup expansion, sustainable innovation and collaboration.

Furthermore, HKSTP will host a Global Mixer, curated pitching sessions, executive sharing and targeted networking events to open doors for commercialisation, licensing, partnerships, investment and international expansion.
Featured Hong Kong startups at BIO 2026:

GenEditBio — Specializes in developing in vivo genome editing therapies (also known as "DNA surgery") by discovering novel Cas nucleases and creating fundamentally safe, efficient and affordable in vivo delivery technologies to treat genetic mutation-related diseases.

Dr. Xia JIN, CEO and Co-Founder of Immuno Cure, shared that their first-in-class HIV therapeutic DNA vaccine, ICVAX, has completed a Phase I clinical trial with promising results. At US BIO 2026, the company will announce encouraging IIT efficacy results for ICVAX and a collaboration with a renowned corporation.

Immuno Cure — Focusing on DNA medicines and antibody immunotherapies for infectious diseases, inflammation, and cancers. First-in-class HIV therapeutic DNA vaccine, ICVAX, completed Phase I clinical trial with promising results, and soon enters Phase II clinical trial. Pipeline products also include DNA vaccines and antibody against various cancers are underway in preclinical stage.

Through these missions, HKSTP is not only taking home-grown innovators overseas, but also attracting partners, capital, talent and collaboration into Hong Kong. The goal is clear: position Hong Kong as a super-connector for local startups to access the vast opportunities in markets across the world, vice versa, and to accentuate that momentum into a model of influence.

Hong Kong Science and Technology Parks Corporation (HKSTP) hosted the HKSTP Cell and Gene Therapy (CGT) Showcase 2026 at the Charles K. Kao Auditorium, Hong Kong Science Park on July 30, with support from Invest Hong Kong. The event brought together more than 200 representatives from the healthcare, academic, investment and regulatory sectors, both locally and from overseas. A major milestone announced at the event was that HKSTP partner company Hong Kong Regen Medtech Limited (HKRM) has become the first facility in Hong Kong to be recognised by the Pharmacy and Poisons Board of Hong Kong (PPBHK) as an allogeneic mesenchymal stem cell (MSC) PIC/S GMP manufacturing facility, enabling the production of advanced therapy products for clinical trials.

HKSTP hosted the HKSTP CGT Showcase 2026, bringing together local and overseas I&T enterprises, medical experts, researchers, investors and patient representatives to explore the clinical translation and broader development of cell and gene therapy. Photo source: HKSTP

Mr. Terry Wong, CEO of HKSTP, said in his remarks: “Cell and gene therapy is one of the fastest-growing fields in life and health tech. The establishment of Hong Kong’s first stem cell production facility certified to PIC/S GMP standards at Hong Kong Science Park marks a significant milestone for the city’s life and health tech ecosystem. The significance of this certification goes far beyond technology alone. It signifies not only that production has met the highest international safety standards, but also that patients and their families can choose locally manufactured cell therapy products with confidence and complete trust. This is a tangible achievement that will enable every Hong Kong citizen to benefit directly. As the orchestrator of Hong Kong’s innovation and technology (I&T) ecosystem, HKSTP has been proactively connecting the life and health tech community with partners, investors and academia. Through a diverse range of incubation programmes, we provide our park companies with seed funding, innovation space, world-class infrastructure and regulatory support, helping them overcome challenges in the journey from laboratory research to clinical translation and turning scientific breakthroughs into real therapeutic outcomes for patients. We will continue to drive ecosystem development and fully support local I&T enterprises in bringing research achievements ‘Made in Hong Kong’ to the global stage.”

In his welcome remarks, HKSTP’s CEO Mr. Terry Wong said that HKSTP, as the orchestrator of Hong Kong’s I&T ecosystem, has been actively connecting the life and health tech community with partners, investors and academia. Through a diverse range of incubation programmes, it supports park companies with seed funding, innovation space, world-class infrastructure and regulatory support, helping them advance from laboratory research to clinical translation and turn scientific breakthroughs into real therapeutic outcomes for patients. Photo source: HKSTP

One of the highlights of the event was HKRM, an HKSTP partner company, recently obtaining Hong Kong’s first PIC/S GMP licence for stem cell production and operating the related manufacturing facility at Hong Kong Science Park, marking a key step in advancing the clinical translation of advanced therapies in Hong Kong. PIC/S GMP is internationally recognised as the gold standard for pharmaceutical manufacturing quality. Facilities must undergo rigorous international assessment to ensure that every batch is produced in a strictly controlled environment.

Mr. Stanley Sy, HKRM Co-founder and CEO, said: “HKRM’s attainment of Hong Kong’s first PIC/S GMP certification for stem cell production marks not only an important milestone in the company’s development, but also signifies that Hong Kong now has the critical infrastructure needed to further support the clinical translation of advanced cell therapies. A stringent, internationally recognised manufacturing quality system helps ensure product consistency and traceability, while strengthening the confidence of medical and regulatory authorities in locally manufactured cell-based products. Based at Hong Kong Science Park, HKRM is grateful for the longstanding support of HKSTP. We also look forward to working with research and clinical partners in the Park to bring more promising therapeutic solutions from Hong Kong to the international stage.”

Mr. Stanley Sy, HKRM Co-founder and CEO, highlighted a major milestone in the development of Hong Kong’s first PIC/S GMP stem cell production facility, underscoring the city’s capabilities in high-quality advanced therapy product manufacturing and clinical translation. Photo source: HKSTP

The event also featured first-hand experiences from patients, their families and doctors on their treatment journeys. Park company Mononuclear Therapeutics (MonoTx) operates Hong Kong’s first AABB-accredited public cord blood bank and haematopoietic stem cell apheresis facility at Hong Kong Science Park, with more than 2,000 cord blood units in storage.

Dr. Wendy Cheng, Chief Operating Officer of MonoTx, introduced Hong Kong’s first AABB-accredited public cord blood bank and haematopoietic stem cell apheresis facility at Hong Kong Science Park, with more than 2,000 cord blood units in storage. Photo source: HKSTP

Dr. Wendy Cheng, Chief Operating Officer of MonoTx, joined Professor Leung Tak Yeung and Professor Ronald Wang of the Department of Obstetrics and Gynaecology at The Chinese University of Hong Kong (CUHK) to share research findings and patient cases with patient families.

Professor Tak Yeung Leung of the Department of Obstetrics and Gynaecology at CUHK (left), together with a patient family (right), shared on stage a research approach for foetuses with severe alpha-thalassaemia, in which the mother’s stem cells are processed by MonoTx and infused into the foetus to investigate whether immune tolerance to the mother’s stem cells can be induced, with the aim of improving clinical outcomes. Photo source: HKSTP

Professor Tak Yeung Leung of the Department of Obstetrics and Gynaecology at CUHK (left), together with a patient family (right), shared on stage a research approach for foetuses with severe alpha-thalassaemia, in which the mother’s stem cells are processed by MonoTx and infused into the foetus to investigate whether immune tolerance to the mother’s stem cells can be induced, with the aim of improving clinical outcomes. Photo source: HKSTP

Professor Leung Tak Yeung’s team at CUHK is studying a treatment for foetuses with severe alpha-thalassaemia by processing the mother’s stem cells through MonoTx and infusing them into the foetus, to investigate whether the foetus can develop immune tolerance to the mother’s stem cells and thereby improve clinical outcomes.

Professor Ronald Wang of CUHK shared his team’s work on using cord blood to treat neonatal brain injury, with preliminary findings suggesting that infusion within 48 hours of birth may help repair brain injury and improve the child’s developmental outcomes later in life. Photo source: HKSTP

Professor Ronald Wang’s team is using cord blood to treat neonatal brain injury. Preliminary findings suggest that cord blood infusion within 48 hours of birth may help repair brain injury and improve the child’s developmental outcomes later in life.

Hong Kong Science Park is home to more than 360 life sciences companies, while the number of cell and gene therapy (CGT) enterprises continues to grow, spanning frontier fields such as stem cells, gene editing, personalised cancer vaccines and CAR-T immunotherapy, and addressing diseases including cancer, heart failure and neurodegenerative disorders.

HKSTP will continue to strengthen Hong Kong’s position as an international health and medical innovation hub by accelerating the translation and application of more locally developed R&D outcomes for the benefit of patients, the industry and society. In doing so, it aims to make innovative therapies more accessible and enable Hong Kong to play an even greater role on the global life and health tech stage.